Is Novartis AG (NVS) a Good Buy in the Drug Manufacturers

A rating of 60 puts Novartis AG (NVS) near the middle of the Drug Manufacturers - General industry according to InvestorsObserver. Novartis AG's score of 60 means it scores higher than 60% of stocks in the industry. Novartis AG also received an overall rating of 53, putting it above 53% of all stocks. Drug Manufacturers - General is ranked 48 out of the 148 industries.

NVS has an Overall Score of 53. Find out what this means to you and get the rest of the rankings on NVS!

See Full NVS Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 53 would rank higher than 53 percent of all stocks. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Novartis AG Stock Today?

Novartis AG (NVS) stock is higher by 0.84% while the S&P 500 has fallen -0.53% as of 11:40 AM on Friday, Mar 24. NVS has gained $0.69 from the previous closing price of $82.51 on volume of 858,924 shares. Over the past year the S&P 500 is down -13.10% while NVS has fallen -3.97%. NVS earned $3.17 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 26.29. Click Here to get the full Stock Report for Novartis AG stock.